U.S. Markets closed
  • S&P 500

    4,136.48
    -43.28 (-1.04%)
     
  • Dow 30

    33,926.01
    -127.93 (-0.38%)
     
  • Nasdaq

    12,006.96
    -193.86 (-1.59%)
     
  • Russell 2000

    1,985.53
    -15.69 (-0.78%)
     
  • Crude Oil

    73.23
    -2.65 (-3.49%)
     
  • Gold

    1,877.70
    -53.10 (-2.75%)
     
  • Silver

    22.40
    -1.22 (-5.17%)
     
  • EUR/USD

    1.0798
    -0.0113 (-1.0366%)
     
  • 10-Yr Bond

    3.5320
    +0.1360 (+4.00%)
     
  • Vix

    18.33
    -0.40 (-2.14%)
     
  • GBP/USD

    1.2056
    -0.0173 (-1.4106%)
     
  • USD/JPY

    131.1500
    +2.5460 (+1.9797%)
     
  • BTC-USD

    23,416.60
    -16.34 (-0.07%)
     
  • CMC Crypto 200

    535.42
    -1.43 (-0.27%)
     
  • FTSE 100

    7,901.80
    +81.64 (+1.04%)
     
  • Nikkei 225

    27,509.46
    +107.41 (+0.39%)
     

Comera Life Sciences to Present Topline Results of SEQURUS-2 Study at 14th Annual Bioprocessing Summit

Comera Life Sciences
Comera Life Sciences

WOBURN, Mass., Aug. 11, 2022 (GLOBE NEWSWIRE) — Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA) (“Company” or “Comera”), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety and convenience, today announced that topline data from its preclinical SEQURUS-2 study will be presented at the 14th Annual Bioprocessing Summit, which will be held in Boston from August 15 – 18, 2022. The Company will also host a booth (#419) in the exhibit hall.

“Many monoclonal antibody (mAb) therapies previously could not be delivered via intravenous injection due to the high viscosity of the therapies at elevated concentrations, but we believe our proprietary SQore™ platform will make subcutaneous (SQ) delivery possible,” said Robert Mahoney, Ph.D., Chief Scientific Officer at Comera. “Comera is using its SQore™ platform to develop excipients, such as caffeine, that interrupt the intermolecular interactions and reduce the viscosity of high concentration mAb formulations to permit SQ delivery.”

SQore Platform Technology Enabling Subcutaneous Administration of Monoclonal Antibody
Yuhong Zeng, Ph.D., Director of Formulation at Comera, will share data on viscosity reduction using Comera’s leading SQore platform technology excipient to enable development of highly concentrated mAb formulations for SQ administration. Topline results from Comera’s recently completed SEQURUS-2 study presentation, titled “Caffeine as a Viscosity Reducer for Highly-Concentrated Monoclonal Antibody Solutions,” will be presented on Thursday, August 18 at 8:30 a.m. ET.

Comera announced favorable topline results of its SEQURUS-1 preclinical study in July, demonstrating supportive evidence of the safety of Comera’s lead caffeine-based proprietary SQore excipient when administered as a SQ biologic drug product formulation with a mAb. SEQURUS-2, a larger study, was designed to expand on the exploratory pharmacokinetic (PK) analysis completed in SEQURUS-1 by providing a statistically robust evaluation of caffeine on the PK of SQ-administered ipilimumab. The in vivo data generated by the two SEQURUS studies complement Comera’s previously published in vitro analytical results in the Journal of Pharmaceutical Sciences that demonstrated favorable viscosity reduction and stability in meeting the criteria for a viable SQ drug product formulation.

About Comera Life Sciences

Leading a compassionate new era in medicine, Comera Life Sciences is applying a deep knowledge of formulation science and technology to transform essential biologic medicines from intravenous (IV) to subcutaneous (SQ) forms. The goal of this approach is to provide patients with the freedom of self-injectable care, reduce institutional dependency and to put patients at the center of their treatment regimen.

To learn more about the Comera Life Sciences mission, as well as the proprietary SQore™ platform, visit https://comeralifesciences.com/.

Forward-Looking Statements

This press release contains includes “forward-looking statements” within the meaning of the federal securities laws including statements regarding our ability to execute on our long term strategy. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this document, including, but not limited to: risks that the recently completed business combination disrupts the Company’s current plans and ability to retain its employees; the Company’s ability to maintain the listing of its securities on the Nasdaq Capital Market; the effect of the COVID-19 pandemic on the Company’s business; the price of the Company’s securities may be volatile due to a variety of factors, including changes in the competitive and highly regulated industries in which the Company plans to operate, variations in performance across competitors, changes in laws and regulations affecting the Company’s business and changes in the capital structure; the ability to implement business plans, forecasts, and other expectations and identify and realize additional opportunities; the risk of downturns and the possibility of rapid change in the highly competitive industry in which the Company operates; the risk that the Company and its current and future collaborators are unable to successfully develop and commercialize the Company’s products or services, or experience significant delays in doing so; the risk that we will be unable to continue to attract and retain third-party collaborators, including collaboration partners and licensors; the risk that the Company may never achieve or sustain profitability; the risk that the Company will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk that the Company experiences difficulties in managing its growth and expanding operations; the risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations; the risk that the Company is unable to secure or protect its intellectual property; the risk that the Company is unable to secure regulatory approval for its product candidates; general economic conditions; and other risks and uncertainties indicated in the Current Report on Form 8-K filed with the SEC on May 25, 2022 under “Risk Factors” and in other filings that have been made or will be made with the SEC. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of Comera’s Current Report on Form 8-K filed with the SEC on May 25, 2022 and other documents filed by Comera from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Comera assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Comera can give no assurance that it will achieve its expectations.

Contacts

Comera Investor
John Woolford
ICR Westwicke
John.Woolford@westwicke.com

Comera Press
Karen Chase
ICR Westwicke
Karen.Chase@westwicke.com